- Home
- IVVD vs EPIX Comparison
IVVD vs EPIX Comparison
Compare IVVD & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- EPIX
- Stock Information
- Founded
- IVVD 2020
- EPIX 2009
- Country
- IVVD United States
- EPIX Canada
- Employees
- IVVD N/A
- EPIX N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- EPIX Health Care
- Exchange
- IVVD Nasdaq
- EPIX Nasdaq
- Market Cap
- IVVD 63.4M
- EPIX 75.9M
- IPO Year
- IVVD 2021
- EPIX N/A
- Fundamental
- Price
- IVVD $0.52
- EPIX $1.93
- Analyst Decision
- IVVD Strong Buy
- EPIX Hold
- Analyst Count
- IVVD 3
- EPIX 3
- Target Price
- IVVD $3.85
- EPIX $2.00
- AVG Volume (30 Days)
- IVVD 1.2M
- EPIX 474.6K
- Earning Date
- IVVD 08-14-2025
- EPIX 08-13-2025
- Dividend Yield
- IVVD N/A
- EPIX N/A
- EPS Growth
- IVVD N/A
- EPIX N/A
- EPS
- IVVD N/A
- EPIX N/A
- Revenue
- IVVD $46,210,000.00
- EPIX N/A
- Revenue This Year
- IVVD $345.16
- EPIX N/A
- Revenue Next Year
- IVVD $161.08
- EPIX N/A
- P/E Ratio
- IVVD N/A
- EPIX N/A
- Revenue Growth
- IVVD 1941.08
- EPIX N/A
- 52 Week Low
- IVVD $0.35
- EPIX $1.40
- 52 Week High
- IVVD $2.74
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- IVVD 32.49
- EPIX 65.49
- Support Level
- IVVD $0.48
- EPIX $1.90
- Resistance Level
- IVVD $0.65
- EPIX $1.93
- Average True Range (ATR)
- IVVD 0.06
- EPIX 0.01
- MACD
- IVVD -0.03
- EPIX -0.00
- Stochastic Oscillator
- IVVD 11.35
- EPIX 85.71
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.